Diagnostic Utility of Endobronchial Ultrasound Guided Mediastinal Lymph Node Sampling in Clinical Stage I and II Non Small Cell Lung Cancer

Inclusion Criteria:

1. Patient must be >/= 18 years old.

2. Patient must have ECOG/Zubrod status 0-2.

3. Patient must have proven or suspected NSCLC (squamous cell, adenocarcinoma, or large
cell) and be clinical Stage I or II, according to the 1998 staging system of the
American Joint Commission on Cancer for lung cancer (T1-3 N0, T1-2 N1).

4. Patient must be eligible for definitive surgical therapy for primary NSCLC.

5. Patient or the patient's legally acceptable representative must provide written
informed consent prior to registration and any study-related procedures.

6. If the patient is a survivor of a prior invasive cancer, all of the following
criteria must apply: a. Patient has undergone potentially curative therapy for all
prior malignancies. b. No evidence of active / recurrent disease.

7. All females of childbearing age must have a negative pregnancy test before beginning
the study.

Exclusion Criteria:

1. Patient has received prior chemotherapy or radiotherapy for this cancer.

2. Patient is considered a poor risk for surgery due to non-malignant systemic disease
(cardiovascular, renal, etc.) that would preclude the treatment options.

3. Patient has contraindication to either endobronchial ultrasound or mediastinoscopy
such as: history of bleeding diathesis, latex allergy, mediastinoscopy, mediastinal
nodal resection, tracheostomy.

4. Patients malignancy consistent with well differentiated (carcinoid) neuroendocrine
histology.

5. Patient has two separate same histology lung tumors (where the question of two
separate primaries or metastatic disease makes definitive clinical staging
inaccurate).

6. Females who are pregnant and/or lactating.